GSA Capital Partners LLP Sells 18,800 Shares of Mirum Pharmaceuticals, Inc. $MIRM

GSA Capital Partners LLP reduced its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 69.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,251 shares of the company’s stock after selling 18,800 shares during the quarter. GSA Capital Partners LLP’s holdings in Mirum Pharmaceuticals were worth $605,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. Emerald Advisers LLC grew its position in Mirum Pharmaceuticals by 20.9% during the 3rd quarter. Emerald Advisers LLC now owns 369,600 shares of the company’s stock worth $27,095,000 after acquiring an additional 63,834 shares during the last quarter. Y Intercept Hong Kong Ltd bought a new stake in Mirum Pharmaceuticals in the third quarter valued at approximately $808,000. Baader Bank Aktiengesellschaft purchased a new stake in shares of Mirum Pharmaceuticals during the third quarter valued at approximately $503,000. Candriam S.C.A. grew its holdings in shares of Mirum Pharmaceuticals by 8.0% in the third quarter. Candriam S.C.A. now owns 403,026 shares of the company’s stock worth $29,546,000 after purchasing an additional 30,021 shares during the last quarter. Finally, TimesSquare Capital Management LLC bought a new position in shares of Mirum Pharmaceuticals in the third quarter worth approximately $22,041,000.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on MIRM. Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a report on Friday, December 19th. Leerink Partners set a $100.00 price target on Mirum Pharmaceuticals in a research report on Wednesday, December 10th. Wall Street Zen upgraded shares of Mirum Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 17th. Evercore reiterated an “outperform” rating and set a $101.00 target price on shares of Mirum Pharmaceuticals in a report on Tuesday, January 20th. Finally, HC Wainwright raised their target price on Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $110.17.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 3,143 shares of the business’s stock in a transaction on Monday, January 26th. The stock was sold at an average price of $96.19, for a total value of $302,325.17. Following the sale, the chief operating officer directly owned 23,286 shares of the company’s stock, valued at approximately $2,239,880.34. The trade was a 11.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Joanne Quan sold 6,911 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $90.27, for a total value of $623,855.97. Following the completion of the sale, the insider directly owned 11,305 shares in the company, valued at approximately $1,020,502.35. This represents a 37.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 45,136 shares of company stock valued at $4,352,029 in the last ninety days. Corporate insiders own 22.87% of the company’s stock.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $105.16 on Monday. The company has a 50 day simple moving average of $90.24 and a two-hundred day simple moving average of $77.94. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $36.88 and a fifty-two week high of $107.41. The company has a market capitalization of $5.40 billion, a price-to-earnings ratio of -122.28 and a beta of 0.49. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.